Incidence and Clearance of Anal Human Papillomavirus (HPV)-16 and HPV-18 Infection, and Their Determinants, Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in France.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
07 04 2020
Historique:
received: 26 09 2019
accepted: 21 11 2019
pubmed: 23 11 2019
medline: 5 2 2021
entrez: 23 11 2019
Statut: ppublish

Résumé

Prospective data on the natural history of anal human papillomavirus (HPV) infection are scarce in human immunodeficiency virus (HIV)-infected men who have sex with men (MSM). We analyzed incidence and clearance of HPV-16 and HPV-18 in a French cohort of HIV-infected MSM, aged ≥35 years, followed-up annually (n = 438, 2014-2018). Human papillomavirus-16 and HPV-18 incidence were similar (~10% incident infections at 24 months). Human papillomavirus-16 incidence was higher among high-grade versus no lesion at baseline (adjusted incidence rate ratio = 3.0; 95% confidence interval, 1.07-8.18). Human papillomavirus-16 cleared significantly slower than HPV-18 (32% versus 54% by 24 months). In conclusion, anal HPV-16 is more persistent than HPV-18, and its incidence correlates with a prior detection of high-grade lesions.

Sections du résumé

BACKGROUND
Prospective data on the natural history of anal human papillomavirus (HPV) infection are scarce in human immunodeficiency virus (HIV)-infected men who have sex with men (MSM).
METHODS
We analyzed incidence and clearance of HPV-16 and HPV-18 in a French cohort of HIV-infected MSM, aged ≥35 years, followed-up annually (n = 438, 2014-2018).
RESULTS
Human papillomavirus-16 and HPV-18 incidence were similar (~10% incident infections at 24 months). Human papillomavirus-16 incidence was higher among high-grade versus no lesion at baseline (adjusted incidence rate ratio = 3.0; 95% confidence interval, 1.07-8.18). Human papillomavirus-16 cleared significantly slower than HPV-18 (32% versus 54% by 24 months).
CONCLUSIONS
In conclusion, anal HPV-16 is more persistent than HPV-18, and its incidence correlates with a prior detection of high-grade lesions.

Identifiants

pubmed: 31754686
pii: 5637552
doi: 10.1093/infdis/jiz623
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1488-1493

Investigateurs

C Arvieux (C)
A Canestri (A)
G M Clifford (GM)
J D Combes (JD)
V Costes-Martineau (V)
J Del Grande (J)
J M Didelot (JM)
I Etienney (I)
M Falguières (M)
T Ferry (T)
H Fischer (H)
J F Flejou (JF)
I Heard (I)
S Henno (S)
N Hoyau (N)
M Landon (M)
H Laude (H)
F Le Breton (F)
A C Lesage (AC)
A Lion (A)
G Maincent (G)
L Marchand (L)
H Njatonirina (H)
O Patey (O)
V Petrov Sanchez (V)
V Pialoux (V)
L Piroth (L)
I Poizot-Martin (I)
O Zaegel-Faucher (O)
E Ressiot (E)
S Radenne (S)
J Reynes (J)
L Siproudhis (L)
C Tamalet (C)
P Tattevin (P)

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Catharina J Alberts (CJ)

International Agency for Research on Cancer, Lyon, France.

Isabelle Heard (I)

Centre National de Référence des HPV, Institut Pasteur, Paris, France.
Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Ana Canestri (A)

Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, AP-HP, Paris, France.

Lucie Marchand (L)

ANRS (France Recherche Nord et Sud Sida-HIV et Hépatites), Paris, France.

Jean-François Fléjou (JF)

Service d'Anatomie et Cytologie Pathologiques, Hôpital Saint-Antoine, Groupe Hospitalier Hôpitaux Universitaires Est Parisien (GH HUEP), AP-HP, Paris, France.
Faculté de Médecine Sorbonne Université, Paris, France.

Lionel Piroth (L)

Département d'Infectiologie, Centre Hospitalier Universitaire (CHU) de Dijon, Dijon, France.
Institut National de la Sante et de la Recherche Medicale (INSERM) Centre d'Investigation Clinique (CIC) 1432, Université de Bourgogne, Dijon, France.

Tristan Ferry (T)

Département d'Infectiologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

Jean-Michel Didelot (JM)

Département d'Hépato-Gastroentérologie, CHU Saint Eloi et Université de Montpellier, Montpellier, France.

Laurent Siproudhis (L)

Department of Gastroenterology, University Hospital of Rennes, Pontchaillou, Rennes, France.
INSERM U1241, University of Rennes 1, Rennes, France.
INPHY CIC 1414 University Hospital of Rennes, Pontchaillou, Rennes, France.

Sébastien Henno (S)

Service d'Anatomie et Cytologie Pathologiques, CHU Pontchaillou, Rennes, France.

Isabelle Poizot-Martin (I)

Service d'Immuno-Hématologie Clinique, Université Aix Marseille, APHM Sainte-Marguerite, Marseille, France.
INSERM U912 (Sciences économiques et sociales de la santé et traitement de l'information médicale - SESSTIM), Marseille, France.

Teresa M Darragh (TM)

Department of Pathology, University of California San Francisco, San Francisco, California, USA.

Gary M Clifford (GM)

International Agency for Research on Cancer, Lyon, France.

Jean-Damien Combes (JD)

International Agency for Research on Cancer, Lyon, France.

Isabelle Etienney (I)

Service de Proctologie Médico-Interventionnelle, Groupe Hospitalier Diaconesses Croix-Saint-Simon, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH